全文获取类型
收费全文 | 4774篇 |
免费 | 314篇 |
国内免费 | 159篇 |
专业分类
耳鼻咽喉 | 7篇 |
儿科学 | 61篇 |
妇产科学 | 29篇 |
基础医学 | 278篇 |
口腔科学 | 26篇 |
临床医学 | 390篇 |
内科学 | 1045篇 |
皮肤病学 | 20篇 |
神经病学 | 101篇 |
特种医学 | 208篇 |
外科学 | 244篇 |
综合类 | 705篇 |
预防医学 | 265篇 |
眼科学 | 38篇 |
药学 | 1287篇 |
中国医学 | 304篇 |
肿瘤学 | 239篇 |
出版年
2024年 | 9篇 |
2023年 | 81篇 |
2022年 | 147篇 |
2021年 | 166篇 |
2020年 | 143篇 |
2019年 | 149篇 |
2018年 | 177篇 |
2017年 | 143篇 |
2016年 | 126篇 |
2015年 | 145篇 |
2014年 | 273篇 |
2013年 | 349篇 |
2012年 | 210篇 |
2011年 | 290篇 |
2010年 | 225篇 |
2009年 | 217篇 |
2008年 | 246篇 |
2007年 | 244篇 |
2006年 | 205篇 |
2005年 | 213篇 |
2004年 | 200篇 |
2003年 | 181篇 |
2002年 | 179篇 |
2001年 | 189篇 |
2000年 | 171篇 |
1999年 | 133篇 |
1998年 | 101篇 |
1997年 | 76篇 |
1996年 | 47篇 |
1995年 | 28篇 |
1994年 | 31篇 |
1993年 | 23篇 |
1992年 | 19篇 |
1991年 | 13篇 |
1990年 | 15篇 |
1989年 | 16篇 |
1988年 | 12篇 |
1987年 | 12篇 |
1986年 | 4篇 |
1985年 | 8篇 |
1984年 | 8篇 |
1983年 | 3篇 |
1982年 | 5篇 |
1981年 | 4篇 |
1979年 | 4篇 |
1978年 | 1篇 |
1977年 | 2篇 |
1975年 | 1篇 |
1972年 | 1篇 |
1967年 | 1篇 |
排序方式: 共有5247条查询结果,搜索用时 31 毫秒
1.
Her-Shyong Shiah Nai-Jung Chiang Chia-Chi Lin Chia-Jui Yen Hui-Jen Tsai Shang-Yin Wu Wu-Chou Su Kwang-Yu Chang Ching-Chiung Wang Jang-Yang Chang Li-Tzong Chen 《The oncologist》2021,26(4):e567-e579
Lessons Learned
- SCB01A is a novel microtubule inhibitor with vascular disrupting activity.
- This first‐in‐human study demonstrated SCB01A safety, pharmacokinetics, and preliminary antitumor activity.
- SCB01A is safe and well tolerated in patients with advanced solid malignancies with manageable neurotoxicity.
2.
3.
Whitney S. Brandt Wanpu Yan Jian Zhou Kay See Tan Joseph Montecalvo Bernard J. Park Prasad S. Adusumilli James Huang Matthew J. Bott Valerie W. Rusch Daniela Molena William D. Travis Mark G. Kris Jamie E. Chaft David R. Jones 《The Journal of thoracic and cardiovascular surgery》2019,157(2):743-753.e3
Objective
Comparative survival between neoadjuvant chemotherapy and adjuvant chemotherapy for patients with cT2-4N0-1M0 non–small cell lung cancer has not been extensively studied.Methods
Patients with cT2-4N0-1M0 non–small cell lung cancer who received platinum-based chemotherapy were retrospectively identified. Exclusion criteria included stage IV disease, induction radiotherapy, and targeted therapy. The primary end point was disease-free survival. Secondary end points were overall survival, chemotherapy tolerance, and ability of Response Evaluation Criteria In Solid Tumors response to predict survival. Survival was estimated using the Kaplan–Meier method, compared using the log-rank test and Cox proportional hazards models, and stratified using matched pairs after propensity score matching.Results
In total, 330 patients met the inclusion criteria (n = 92/group after propensity-score matching; median follow-up, 42 months). Five-year disease-free survival was 49% (95% confidence interval, 39-61) for neoadjuvant chemotherapy versus 48% (95% confidence interval, 38-61) for adjuvant chemotherapy (P = .70). On multivariable analysis, disease-free survival was not associated with neoadjuvant chemotherapy or adjuvant chemotherapy (hazard ratio, 1.1; 95% confidence interval, 0.64-1.90; P = .737), nor was overall survival (hazard ratio, 1.21; 95% confidence interval, 0.63-2.30; P = .572). The neoadjuvant chemotherapy group was more likely to receive full doses and cycles of chemotherapy (P = .014/0.005) and had fewer grade 3 or greater toxicities (P = .001). Response Evaluation Criteria In Solid Tumors response to neoadjuvant chemotherapy was associated with disease-free survival (P = .035); 15% of patients receiving neoadjuvant chemotherapy (14/92) had a major pathologic response.Conclusions
Timing of chemotherapy, before or after surgery, is not associated with an improvement in overall or disease-free survival among patients with cT2-4N0-1M0 non–small cell lung cancer who undergo complete surgical resection. 相似文献4.
Matthew D. Li Katrina F. Chu Allegra DePietro Vincent Wu Eric Wehrenberg-Klee Omar Zurkiya Raymond W. Liu Suvranu Ganguli 《Journal of vascular and interventional radiology : JVIR》2019,30(3):314-319
Purpose
To evaluate the feasibility of a same-day yttrium-90 (90Y) radioembolization protocol with resin microspheres (including pretreatment angiography, lung shunt fraction [LSF] determination, and radioembolization) for the treatment of hepatocellular carcinoma (HCC) and liver metastases.Materials and Methods
All same-day radioembolization procedures performed over 1 y (February 2017 to January 2018) were included in this single-institutional retrospective analysis, in which 34 procedures were performed in 26 patients (median age, 63 y; 13 women), 19 with liver metastases and 7 with HCC. Yttrium-90 treatment activities were calculated by body surface area method. Tumor imaging response was assessed by Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 for liver metastases and modified RECIST for HCC. Clinical side effects and adverse events were graded per Common Terminology Criteria for Adverse Events version 4.0.Results
All planned cases were technically successful, and no cases were canceled for elevated LSF or vascular anatomic reasons. Pretreatment angiography modified the planned 90Y treatment activity in 1 case in which vascular anatomy required a lobar-dose split into 2 for segmental infusions. In 18% of cases, patients were briefly admitted after the procedure for observation or symptom management. Imaging evaluation of initial efficacy at 1 month demonstrated partial response in 25% and stable disease in 67% of patients with liver metastases and partial/complete response in 43% and stable disease in 14% of patients with HCC. Grade ≥ 3 adverse events occurred in 6% of cases, with no systemic therapy–limiting toxicities. The mean total procedure time was 4.2 hours.Conclusions
A same-day 90Y radioembolization protocol with resin microspheres is feasible in select patients, which can expedite cancer therapy. 相似文献5.
目的 观察多巴酚丁胺负荷期间QT离散度(QTd)的变化情况,探讨其临床意义.方法 对13只小型中国家猪采用闭胸介入法制备急性冬眠心肌模型(右冠状动脉为靶血管),利用多巴酚丁胺超声负荷实验(DSE,0~40 μg·Kg-1·min-1)检出冬眠心肌,之后成功复灌,处死动物,对心脏行TTC大体染色及光镜检查.分别于模型制备前后、DSE期间及复灌后观察QTd的变化情况.结果 ①10只动物(76.92%)成功制备成模型,病理检查未示心肌坏死改变.②模型制备成功后QTd较正常状态明显增加[(68.75±5.33)ms和(25.00±1.77)ms,P<0.05];复灌后明显降低[(35.62±3.47)ms和(68.75±5.33)ms,P<0.05],与正常状态差异无统计学意义[(35.62±3.47)ms和(25.00±1.77)ms,P>0.05].③DSE期间QTd呈现先降低后增加的双相反应的变化趋势.④模型制备成功后的QTd与DSE检出的急性冬眠心肌节段数呈中等程度的负相关(r=-0.64,P<0.05).结论 ①.急性冬眠心肌动物模型的QTd明显增加,早期有效复灌可降低QTd.②DSE期间急性冬眠心肌模型的QTd呈现双相反应趋势.③急性冬眠心肌模型的QTd是反映冬眠心肌数量的指标之一. 相似文献
6.
QT离散度对急危重病人预后的评估 总被引:1,自引:0,他引:1
目的 研究QT离散度对急危重病人预后的预测价值。方法 死亡组 4 7例、疾病组 4 0例和正常组 4 3例。记录 12导联心电图 ,人工测量各导联R -R间期和QT间期 ,计算R -R、QTc、QTd和QTcd。结果 死亡组的R -R、QTc、QTd和QTcd分别为 0 5 6 2± 0 2 2 0ms、0 35 6± 0 0 6 9ms、0 0 5 6± 0 0 33ms和 0 0 79± 0 0 4 6ms ;疾病组的R -R、QTc、QTd和QTcd分别为0 80± 0 134ms、0 4 16± 0 0 3ms、0 0 34± 0 0 14ms和 0 0 39± 0 0 16ms;正常组的R -R、QTc、QTd和QTcd分别为 0 82 5± 0 0 88ms、0 4 0 2± 0 0 3ms、0 0 2 7± 0 0 15ms和 0 0 31± 0 0 15ms。比较死亡组、疾病组和正常组发现 ,死亡组和疾病组的R -R、QTc、QTd和QTcd存在显著差异 (P分别 <0 0 0 1、<0 0 0 2 5、<0 0 0 1和 <0 0 0 1)。死亡组和正常组的R -R、QTc、QTd和QTcd存在显著差异 (P分别 <0 0 0 1、<0 0 0 2 5、<0 0 0 1和 <0 0 0 1)。结论 QTd对急危重病人的预后有一定的预测价值 ;但其它临床应用价值存在局限性 ,有待进一步探索。 相似文献
7.
目的 :观察改良极化液治疗慢性充血性心力衰竭 (CHF)前后QTd、QTcd变化 ,探讨它对CHF近期预后影响。方法 :将80例住院CHF患者随机分为两组 ,A组 4 0例应用改良极化液 (葡萄糖 -胰岛素 -门冬氨酸钾镁液 )治疗 ,B组 4 0例仅静滴葡萄糖。结果 :两组患者RR间期在治疗前后比较有显著差异 (P <0 .0 1) ,A组治疗后QTd、QTcd与治疗前比较有明显缩短 (QTd分别为 90 .2± 4 0 .7与 5 0 .2± 30 .4 ,QTcd分别为 86 .4± 12 .4与 4 6 .2± 12 .4 ,P <0 .0 1) ,治疗后QTd、QTcd两组间比较有显著差异 (QTd为 5 0 .2± 30 .4与 78.9± 2 0 .2 ,QTcd为 4 6 .2± 12 .4与 70 .3± 16 .8,P <0 .0 1) ,两组间洋地黄过量中毒、恶性室性心率失常发生率比较 ,有显著性差异 (P <0 .0 5 )。结论 :改良极化液可明显缩短CHF患者QTd、QTcd ,减少洋地黄过量中毒、恶性室性心率失常发生 ,对CHF近期预后可能有改善作用 相似文献
8.
This case report describes the anaesthetic management of a patient with sporadic-type long QT interval syndrome (LQTS), and increased QT dispersion, who presented for removal of an ovarian cyst. Beta adrenergic blockade and adequate depth of anaesthesia for successful management is emphasized. The Successful use of epidural administration of lignocaine and opioids in addition to general anaesthesia is described. 相似文献
9.
Laurent P. Rivory Michael S. Roberts Susan M. Pond 《Journal of pharmacokinetics and pharmacodynamics》1992,20(1):19-61
An assumption of previous models of hepatic elimination is that there is negligible axial diffusion in the liver. We show, by construction of a stochastic model and analysis of published data, that compounds which are readily diffusible and partitioned into hepatocytes may undergo axial tissue diffusion. The compounds most likely to be affected by axial tissue diffusion are the lipophilic drugs for which the cell membranes provide little resistance and which are highly extracted, thereby creating steep concentration gradients along the sinusoid at steady state. This phenomenon greatly modifies the availability of the compound under conditions of altered hepatic blood flow and protein binding. For moderately diffusible compounds, these relationships are similar to those predicted by the simplistic venous-equilibrium model. Hence, the paradoxical ability of the venous-equilibrium model to describe the steady-state kinetics of lipophilic drugs such as lidocaine, meperidine, and propranolol may be finally resolved. The effects of axial tissue diffusion and vascular dispersion on hepatic availability of drugs are compared. Vascular dispersion is of major importance to the availability of poorly diffusible compounds, whereas axial tissue diffusion becomes increasingly dominant for highly diffusive and partitioned substances.This study was supported by the National Health and Medical Research Council of Australia. 相似文献
10.
从制备方法着手综述了近年来聚苯胺/聚合物导电材料研制开发的最新成果,并简介了聚苯胺/聚合物导电材料的应用情况。 相似文献